Clinical Trials Browser

Urogenital Diseases, Urinary Bladder Diseases, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Neoplasms, Neoplasms by Site, Urogenital Neoplasms, Urologic Diseases, Urologic Neoplasms, Female Urogenital Diseases, Male Urogenital Diseases

NCT06211764 2026-05-08

SunRISe-5

Phase 3 Active not recruiting

272 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms

NCT06919965 2026-05-08

MoonRISe-3

Phase 3 Recruiting

220 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms

NCT04166318 2026-05-05

Lower-Dose Chemoradiation in Treating Patients With Early-Stage Anal Cancer, the DECREASE Study

Phase 2 Active not recruiting

252 enrolled

Gastrointestinal

Anal Canal Carcinoma, Anus Neoplasms

NCT03775265 2026-05-04

Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer

Phase 3 Active not recruiting

475 enrolled

Genitourinary

Urinary Bladder Neoplasms

NCT07097142 2026-05-04

Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study

Phase 3 Recruiting

486 enrolled

Genitourinary

Urinary Bladder Neoplasms

NCT04241185 2026-05-01

MK-3475-992

Phase 3 Active not recruiting

520 enrolled

Genitourinary

Urinary Bladder Neoplasms

NCT06774131 2026-04-29

A Phase 3 Single-arm Study of UGN-104 for the Treatment of Low-grade Upper Tract Urothelial Cancer

Phase 3 Recruiting

70 enrolled

Genitourinary

Carcinoma, Transitional Cell

NCT04847063 2026-04-14

Individual Response to Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Treatment of Peritoneal Carcinomatosis From Peritoneal Mesothelioma or Atypical Mesothelial Proliferation or From Ovarian, Colorectal, or Appendiceal Histologies

Phase 1 Recruiting

60 enrolled

GastrointestinalGynecologic

Appendiceal Neoplasms, Gastrointestinal Neoplasms, Necrosis, Ovarian Neoplasms, Peritoneal Neoplasms, Colorectal Neoplasms

NCT06388720 2026-04-13

IMGeS

Phase 2 Recruiting

82 enrolled

Genitourinary

Urinary Bladder Neoplasms

NCT04779554 2026-04-01

Flat Dose vs. Weight-based IP Chemotherapy for CRS/HIPEC

Phase 2 Recruiting

100 enrolled

GastrointestinalGynecologic

Appendiceal Neoplasms, Peritoneal Neoplasms, Pseudomyxoma Peritonei, Colorectal Neoplasms

NCT06704191 2026-03-30

In-home Intravesical Chemotherapy for the Treatment of Bladder Cancer, INVITE Trial

Phase 1/2 Recruiting

40 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT05672108 2026-03-05

Phase II Trial of Lung Chemoemobolization

Phase 2 Recruiting

30 enrolled

GastrointestinalSarcomaThoracic

Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Mediastinal Neoplasms, Pleural Neoplasms, Sarcoma

NCT03348969 2026-03-03

NICSA

Phase 4 Completed

120 enrolled

Genitourinary

Urinary Bladder Neoplasms

Clinical Trials

TIM

Risk Enabled Therapy After Initiating Neoadjuvant Chemotherapy for Bladder Cancer (RETAIN)

A Study of Chemotherapy and Radiation Therapy Compared to Chemotherapy and Radiation Therapy Plus MEDI4736 (Durvalumab) Immunotherapy for Bladder Cancer Which Has Spread to the Lymph Nodes, INSPIRE Trial

Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial

Safety and Efficacy of PIPAC Using Single Agent Mitomycin in Solid Tumors

Consolidative Therapy After EV + Pembrolizumab in Muscle Invasive Bladder Cancer, REINFORCE Trial

Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer

ENVISION

EV-309

SunRISe-5

MoonRISe-3

Lower-Dose Chemoradiation in Treating Patients With Early-Stage Anal Cancer, the DECREASE Study

Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer

Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study

MK-3475-992

A Phase 3 Single-arm Study of UGN-104 for the Treatment of Low-grade Upper Tract Urothelial Cancer

Individual Response to Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Treatment of Peritoneal Carcinomatosis From Peritoneal Mesothelioma or Atypical Mesothelial Proliferation or From Ovarian, Colorectal, or Appendiceal Histologies

IMGeS

Flat Dose vs. Weight-based IP Chemotherapy for CRS/HIPEC

In-home Intravesical Chemotherapy for the Treatment of Bladder Cancer, INVITE Trial

Phase II Trial of Lung Chemoemobolization

NICSA